Directory Tag cannabis news

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

[stock_market_widget type=”combo” symbol=”GWPH” template=”tablechart” color=”default” fields=”virtual.symbol,virtual.name,quote.regularMarketPrice,quote.regularMarketChange,quote.regularMarketChangePercent” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]

HONEYSUCKLE is a print and digital publication that emphasizes diverse voices and visual impact. Each quarter, our print edition explores a topical issue through a range of perspectives. Our intimate style of reporting combines input from high-profile celebrities, leaders in various fields, and personal testimony. Online, we expand the conversation in daily posts that include journalism, first-person essays, reviews and poetry. Our cross-generational audience is open, inclusive, and curious, united by their shared passion for knowledge and desire to dive deep into important themes that shape our time.

To date, our print editions have covered topics such as women’s roles and rights, home and homelessness, cannabis as a growing and politically charged industry, and the evolution of sex in our culture. Our covers have featured Oscar nominee Kirsten Dunst, iconic activist actor Alan Cumming, bi-racial model/rapper and homelessness activist Justin Bullock. Major features include Oscar winner Holly Hunter, NFL legend and cannabis advocate/entrepreneur Marvin Washington; Bruce Giffin, acclaimed photojournalist from Detroit, and more. High-quality color printing enables us to refract our topics through photography, painting, and illustration, bringing vibrancy to each page.

National print distribution, inclusion in industry gift bags at events such as New York Fashion Week and SXSW, and a thriving online presence enable HONEYSUCKLE to reach a richly varied audience. Unlike many publications, we do not adapt our material to a given demographic. Rather, we assume that our readers’ interests are broad, and that cross-cultural and cross-generational exchange is vital. In an age of polarity, we seek to soften boundaries and spread information that creates respectful dialogue and action. In as much as human lives are defined by what we care about, we bring that passion to our pages.

Topics we plan to discuss are Sustainability, Quantum Thinking and Social issues.

“Founded by filmmaker Ronit Pinto, Honeysuckle is devoted to expression through all forms of media and offers a unique approach to video storytelling. Through our in-house production company Black Neon Media (staffed by professionals who have worked with Wes Craven, Michael Bay, and Steven Spielberg), as well as collaborations with other dynamic collectives, we produce original content that is at once entertaining, informative, and provocative. In film we aim to push the artistic envelope while composing thoughtful and engaging narratives which center on themes including sexuality, spirituality, violence, activism, and technological innovation.”

iAnthus Capital Holdings, Inc. engages in the delivery of solutions for financing, developing, and managing state-licensed cannabis cultivators and dispensaries in the United States. The company is headquartered in New York, New York.

[stock_market_widget type=”chart” symbol=”ITHUF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops novel and cannabinoid-based therapies. The company’s lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa (EB). The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, arthritis disease areas, and others. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750 targeted as a therapy in EB and other dermatological and wound-healing applications; and a research and development collaboration agreement with ATERA SAS to develop 3D human skin models of EB to evaluate the in vitro drug efficacy of INM-750. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

[stock_market_widget type=”chart” symbol=”IMLFF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]

Kush Bottles, Inc. is a dynamic sales and distribution platform that provides unique products and services for both businesses and consumers in the cannabis industry.

Founded in 2010 as a packaging and supplies company for dispensaries and growers, Kush Bottles has sold more than 1 billion units and now regularly services more than 5,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe.

The company has facilities in the three largest U.S. cannabis markets and a local sales presence in every major U.S. cannabis market. Kush Bottles aims to be the gold standard for responsible and compliant products and services in the cannabis industry. Kush Bottles has no direct involvement with cannabis plants or extracts.

Informational Videos

[stock_market_widget type=”combo” symbol=”KSHB” template=”tablechart” color=”default” fields=”virtual.symbol,virtual.name,quote.regularMarketPrice,quote.regularMarketChange,quote.regularMarketChangePercent” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]